# PARRC (pembrolizumab): what clinicians are saying

> 7 statements from 6 sources (6 posts), 4 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
- NCT ID: NCT06770582
- Registry: https://clinicaltrials.gov/study/NCT06770582
- Sponsor: National Cancer Institute (NCI)
- Phase: Phase 2
- Status: Recruiting
- Drugs tested: pembrolizumab
- Indication: high-grade T1 bladder cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: 280dbd99fce2a08f66a8e44495127293d894aa6465b86f49fc4553abba353082

## Counts

- Commentary sources screened: 26
- Sources cited by verified statements: 6
- Verified statements: 7
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 4
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 4
- Speakers cited: 3
- Cited speakers with a verified identity: 3
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 3
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 3
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Radiation oncology
  - 1 physician, Urology
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A radiation oncologist whose trial involvement is unconfirmed encouraged participation in PARRC; a urologist responded favorably to its launch. Neither comment expressed a treatment preference. The broader treatment context tentatively raised chemoradiation alongside a reported audience preference for cystectomy, relaying a presentation by a speaker described as a trial principal investigator. An enrollment suggestion in BCG-unresponsive CIS left eligibility unclear. The comments do not assess comparative benefit, safety or quality-of-life trade-offs.

## Question clinicians left open

In PARRC’s setting of BCG-unresponsive high-grade T1 bladder cancer, could chemoradiation be considered instead of cystectomy?

From finding F1 (2 statements from 1 speaker in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F2. PARRC: a clinician encourages opening and accrual; one welcomes activation
  - 2 statements from 2 speakers in 2 sources.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one welcomes activation”.
  - 2 of the report's 3 cited clinicians.
- F1. BCG-unresponsive NMIBC: a clinician relays a question on chemoradiation vs cystectomy
  - 2 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.

### Beyond the trial population

- F3. BCG-unresponsive CIS: a clinician proposes enrollment in NRG GU014
  - 2 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 3 cited clinicians.

1 of the 3 findings and 2 of the 7 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F2 | 2 | 3 | 2 | 2 | 3 |
| F1 | 2 | 2 | 2 | 1 | 4 |
| F3 | 2 | 4 | 3 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F2 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 2 posts and articles |
| F1 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 2 posts and articles |
| F3 | 1 | 0 | 0 | 0 | 1 | 3 | 1 | 3 posts and articles |

### Trial dimensions

- Primary endpoint: Bladder intact event-free survival (BIEFS): no finding draws on it directly
- Primary endpoint: Global quality of life: no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (2 shared claims)
- The comparison: no finding draws on it directly
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (2 shared claims), F1 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 7 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 3 of the 3 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

4 discussed · 5 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Bladder intact event-free survival (BIEFS) | no commentary found | 0 | 0 |
| Primary endpoint: Global quality of life | no commentary found | 0 | 0 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 2 | 2 |
| The comparison (The registered arms and what clinicians said about how they compare.) | no commentary found | 0 | 0 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 3 | 3 |
| Cystectomy versus consideration of chemoradiation | discussed | 2 | 2 |
| Enrollment suggestion within a BCG-unresponsive CIS exchange | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 0 statements · 0%** | | | |
| YouTube | 0 | 0 | 1 |
| **Posts · 7 statements · 100%** | | | |
| X threads | 7 | 6 | 19 |
| Bluesky threads | 0 | 0 | 6 |

- Screened window: 2025-01-17 to 2026-11-19
- Cited window: 2025-02-14 to 2026-08-28
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
- Registry: NCT06770582 (https://clinicaltrials.gov/study/NCT06770582)
- Study IDs: NCI-2025-00008 · NRG-GU014 (NRG Oncology; CTEP) · U10CA180868
- Sponsor: National Cancer Institute (NCI)
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Recruiting
- Enrollment: 160 (estimated)
- Start: 2025-06-03 (actual)
- Primary completion: 2032-02-01 (estimated)
- Primary endpoint: Bladder intact event-free survival (BIEFS) (Up to 5 years)
- Primary endpoint: Global quality of life (Up to 5 years)
- Intervention: Biospecimen Collection (procedure)
- Intervention: Cisplatin (drug)
- Intervention: Computed Tomography (procedure)
- Intervention: Fluorouracil (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Magnetic Resonance Imaging (procedure)
- Intervention: Mitomycin (drug)
- Intervention: Pembrolizumab (biological)
- Intervention: Questionnaire Administration (other)
- Intervention: Radiation Therapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on economic and patient-goal trade-offs in sequencing bladder-sparing treatments versus cystectomy.
- 21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 35 sources about other trials or topics are not included; discussion that uses 2 names the trial shares with other things, without the trial's condition or setting, may be missing.
- Brief social-media statements provide little explanation of patient selection, treatment trade-offs or practical implementation; their strength should not be expanded into prescribing recommendations.
- A reported audience preference and organizational repetition do not establish independent clinician consensus.
- Discussion that did not name the trial or used different wording may be absent, so the report is not representative of all public or HCP discussion.
- No full protocol or exact-trial results publication accompanies these views in the sources reviewed for this edition; the posts do not support a comprehensive appraisal of methods or outcomes.
- The linked-article quotation about unmet need is incomplete and does not identify its speaker, so it cannot be assigned to a named clinician.
- The enrollment suggestion made in the CIS exchange does not establish which patients would satisfy PARRC eligibility.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 7 verified statements · 4 from 3 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (3 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/parrc-nct06770582
- Agents: POST https://www.erudio.com/api/orders with {"report": "parrc-nct06770582", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=parrc-nct06770582

## Cite

Erudio Health. PARRC (NCT06770582): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/parrc-nct06770582

## Questions

### How much does the PARRC report cost?

One edition costs $750 (Focused · 7 verified statements · 4 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the PARRC report cover?

7 statements from 6 sources (6 posts), 4 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the PARRC report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "parrc-nct06770582" }) previews it and create_order({ "report": "parrc-nct06770582", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the PARRC report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/parrc-nct06770582.json
- Markdown: https://www.erudio.com/reports/parrc-nct06770582.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/parrc-nct06770582/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "parrc-nct06770582"}`
